Cancer is a disease of the genome, often evidenced by rampant genomic instability in tumour cells leading to pervasive mutational or chromosomal abnormalities. Large-scale sequencing efforts have generated comprehensive catalogues of the key genomic changes in many types of cancer, thus identifying potentially clinically actionable abnormalities 1 . Because of these findings, clinical sequencing is increasingly being used in the management of patients with cancer, especially through genome-driven clinical trials designed to select a targeted therapy on the basis of the genomic profile of an individual tumour 2, 3 . The use of this personalized approach has been highly successful in subsets of patients 4 , such as those with chronic myelogenous leukaemia harbouring the BCR-ABL translocation, patients with HER2 amplified breast cancer, patients with BRAF-mutant melanoma and those with non-small-cell lung cancer (SRM/MRM) mass spectrometry (MS) into the clinical laboratory to facilitate clinical proteogenomics.
Connecting genotype to phenotype
On the basis of first principles, the observation that exclusive use of tumour genomic profiles is often insufficient to guide the reliable selection of targeted therapies should not be considered surprising. Many cellular processes downstream of the genome determine, or influence, which aspects of the cancer genome affect the phenotype of cancer cells (Fig. 1 ). For example, epigenetic changes are common in human cancers and affect the expression of critical cancer-related genes [11] [12] [13] [14] , such as oncogenes and tumour suppressors, and can also affect other regulatory elements such as microRNAs (miRNAs), with implications for cellular signalling and homeostasis 13 . Histone modifications have a role in alternative splicing 15 , which helps to drive hallmarks of cancer 16, 17 . Genomic, epigenomic and transcriptomic alterations all ultimately affect the activity of proteins expressed in tumours, which are also regulated by other processes such as protein translation, post-translational modifications such as phosphorylation, glycosylation and acetylation, and protein degradation. Thus, tumour mutational profiles are only one of many potential determinants of responsiveness to targeted therapies, and an exclusive focus on genomic profiles omits various important aspects of tumour biology that can only be detected downstream of the genome and might affect responsiveness to such therapies.
The majority of molecularly targeted therapies, such as kinase inhibitors, poly(ADP-ribose) polymerase (PARP) inhibitors and therapies targeting immunomodulatory proteins, do not directly target the cancer genome but rather target proteins in cancer cells. Thus, understanding and quantifying the expression of target proteins throughout all phases of personalized oncology, from drug development to patient selection, are critically important. For example, investigators need to determine whether the target protein is expressed in the target tissue and to what extent. Further details, (NSCLC) harbouring EGFR mutations or ALK rearrangements. However, important challenges remain [5] [6] [7] [8] [9] [10] , most notably the lower than expected response rates to targeted therapies in patients predicted to be responsive on the basis of the genomic profiles of their tumours and the ultimate emergence of drug-resistant disease in the vast majority of patients. Thus, although genome-driven oncology has prolonged the survival durations of subsets of patients with cancer, considerably more information on tumour biology, which is not apparent from the genomic profiles of tumours, must be elucidated before personalized oncology can become broadly applicable and effective 10 . In this Perspective, we discuss the added value of proteogenomics over the purely genome-driven approach to the clinical characterization of cancers and summarize ongoing efforts to incorporate targeted proteomic measurements based on selected/multiple reaction monitoring Abstract | Cancer genomics research aims to advance personalized oncology by finding and targeting specific genetic alterations associated with cancers. In genome-driven oncology , treatments are selected for individual patients on the basis of the findings of tumour genome sequencing. This personalized approach has prolonged the survival of subsets of patients with cancer. However, many patients do not respond to the predicted therapies based on the genomic profiles of their tumours. Furthermore, studies pairing genomic and proteomic analyses of samples from the same tumours have shown that the proteome contains novel information that cannot be discerned through genomic analysis alone. This observation has led to the concept of proteogenomics, in which both types of data are leveraged for a more complete view of tumour biology that might enable patients to be more successfully matched to effective treatments than they would using genomics alone. In this Perspective, we discuss the added value of proteogenomics over the current genome-driven approach to the clinical characterization of cancers and summarize current efforts to incorporate targeted proteomic measurements based on selected/multiple reaction monitoring (SRM/MRM) mass spectrometry into the clinical laboratory to facilitate clinical proteogenomics.
such as how the compound is able to engage the target, the exposure-response relationship and the presence or absence of crosstalk between signalling pathways, are similarly important as these can have implications for drug resistance and/or synergistic effects. Finally, an improved understanding of the variability in target protein expression and cellular responses to therapy across different patient populations is required in order to improve patient selection.
MS-based proteomics
During the past decade, untargeted ('shotgun') MS-based proteomics has evolved as a powerful technology that enables the proteome-wide detection and quantification of proteins in complex samples (Fig. 2) . In these analyses, proteins extracted from biological samples, such as tumour specimens, are enzymatically digested into peptides and then analysed using liquid chromatography−tandem mass spectrometry (LC−MS/MS). To reduce sample complexity, the peptides can be fractionated before LC−MS/MS, which serves to increase the level of proteome coverage but has the drawback of decreasing sample throughput and increasing costs. Alternatively, advances in instrumentation and methods involving the use of long chromatographic columns have enabled the analysis of unfractionated samples with only modest reductions in protein detection compared with use of pre-fractionated samples 18, 19 . These advances have the potential to substantially increase the number of samples that can be profiled within a reasonable time frame. Following acquisition of LC−MS/MS data, computational algorithms are used to analyse the resulting precursor (peptide) ion spectra and tandem mass spectra to enable peptide and protein detection and quantification 20 . Relative quantification can be performed using one of two methods: label-free or isobaric labelling approaches. In label-free analysis, each sample is analysed separately, and proteins are quantified on the basis of precursor ion intensity or the number of associated fragment spectra. By contrast, isobaric labelling methods 21 , for example, isobaric tag for relative and absolute quantification (ITRAQ) and tandem mass tags, enable sample multiplexing (the simultaneous analysis of multiple samples), and quantification is based on the relative intensities of the reporter ions in fragment spectra. Advances in both instrumentation and sample preparation protocols have enabled near proteome-wide quantitative measurements at a single amino acid level of resolution, which enables proteomics to join forces with genomics for the comprehensive molecular characterization of tumour material -that is, proteogenomics 22 .
Proteogenomics-driven discovery
Proteogenomics is the fusion of proteomics and genomics, in which hypotheses generated by genomic observations are tested at the protein level, interpretations of protein abundance and the extent of modification are guided by knowledge of the genome of the specific tumours that are under investigation and genomic and proteomic measurements are integrated in order to understand and predict cancer phenotypes. The National Cancer Institute (NCI) has funded a major cancer proteogenomics effort through its Clinical Proteomic Tumour Analysis Consortium (CPTAC). The three CPTAC flagship reports on colorectal 23 , breast 24 and ovarian 25 cancers provide a resource for the cancer research community, both by indicating which of the genomic and transcriptomic features of these cancers are recapitulated at the protein level and by providing new insights into the substantial effects of post-translational modifications, specifically phosphorylation and acetylation, on the functional activities of proteins associated with DNA repair, cellular proliferation and survival. The proteogenomic approach has also been applied in other studies involving tumour specimens, patient-derived xenograft (PDX) models or cell lines [26] [27] [28] [29] [30] [31] [32] [33] . Multiple reviews on the concept and methods of proteogenomics and its application to cancer research have been published [34] [35] [36] [37] [38] [39] [40] [41] [42] . This section focuses on the added value of proteomics in proteogenomics-driven target discovery. Thoughtful integration of genomic and proteomic data can enhance our knowledge of cancer biology and biomarker and drug target discovery in multiple ways (Fig. 3) .
Detection of novel peptide sequences.
Proteogenomics is becoming a powerful approach for the validation of novel peptide sequences inferred from genomic studies 43 . Investigations of cancer genomics have identified a large number of tumourspecific DNA or RNA sequences, including somatic mutations, novel exon-exon junctions and gene fusions. Proteins or peptides translated from these sequences are promising biomarker candidates, drug targets and neoantigens for use in immunotherapy protocols. The first step towards clinical translation of these genomic discoveries is validation of their expression as proteins. Shotgun LC−MS/MS enables proteome sequencing 44 . However, traditional proteomics data analysis workflows 28, 45 interpret MS/MS spectra using a reference protein sequence database (such as RefSeq or Ensembl) and cannot be used to identify any novel, cancer-specific sequences. The proteogenomic approach incorporates candidate protein sequences derived from exome sequencing or RNA sequencing data into a customized database for the interpretation of MS/MS data, thus enabling the identification of sample-specific peptides that are missing from the reference databases 27, 46 . Using this approach, the CPTAC colorectal 23 , breast 24 Genes are expressed as proteins, which both dictate tumour phenotype and are targeted by the majority of targeted therapies. Many processes downstream of the genes affect protein activity , and thus, for precision oncology , it is important to quantify proteins and protein activities in addition to determining tumour genomic sequences. For example, not all mutated genes are stably expressed as proteins, and genes that are expressed can then be post-translationally modified (with functional consequences). Therefore, precision medicine that relies solely on genomics-based assays will exclude a lot of potentially relevant information. miRNA , microRNA.
proteomic platforms is not comprehensive. For example, genomic, transcriptomic and proteomic data from two PDX models of breast cancer demonstrate that only 10% of the single-nucleotide variants detected using both DNA and RNA sequencing can be observed as peptides, even with substantial chromatographic fractionation of the tumour lysates and up to 30 process replicates 47 . Therefore, although proteomic data provides the ultimate verification of novel, cancer-specific coding sequences, a lack of proteomic evidence does not entirely exclude the existence of the genomically predicted novel peptides. Using multiple proteases with distinct cleavage preferences to generate peptides for analysis might provide an increased level of sequence coverage 48 . Controlling for false-positive identifications is important. When possible, a strict samplespecific customized database derived from matched DNA or RNA sequencing data from the same sample should be used, and only highly confident novel genomic events should be included in the database. The identification of novel peptides tends to result in a higher false discovery rate (FDR) than that associated with known peptides, and therefore a step-wise FDR control scheme should be used to evaluate FDRs for known and novel peptide identifications separately 36 . Other interpretations of a spectrum supporting a novel peptide, such as contaminants or post-translational modifications of known peptides, should be carefully excluded. Eventually, novel peptides identified with a high level of confidence should be validated using targeted proteomic assays.
Advances in both the sensitivity and throughput of MS have enabled the direct interrogation of immunopeptides released from MHC complexes 49 rather than the previous laborious approach requiring analysis of tumour-infiltrating lymphocytes 42, 50 . Putative neoantigens identified using proteogenomic approaches that combine whole-exome sequencing, RNA sequencing and direct MS analysis of the MHC peptidome have proved successful as vaccines promoting an antitumour immune response and are currently approaching investigation in clinical trials 49, 51 .
Prognostic and predictive biomarkers.
Integrative proteogenomic analysis reveals that for many genes, variations in the abundance of mRNAs across tumours are poorly correlated with the variations in abundance of their matched proteins [23] [24] [25] . Although some genes have high levels of mRNA-protein correlation, 30-70% of genes had no statistically significant positive correlation 23, 25 . Thus, for many genes, global mRNA measurements are poor predictors of variations in protein abundance. The lack of mRNA-protein correlation might be partially explained by technical noise associated with both the sequencing and proteomics platforms. In addition, protein profiling data are more closely aligned with function than mRNA profiling data 52 , suggesting that protein translation and degradation are tightly regulated and have a critical role in determining both protein abundance and gene function.
Many studies have identified mRNAs as prognostic biomarkers by associating the level of expression of a specific mRNA, or mRNAs, with patient survival, but very few of these biomarkers have been translated In untargeted (that is, 'shotgun') proteomics, proteins are converted to peptides through proteolytic digestion (typically using trypsin). The peptides are fractionated using liquid chromatography and introduced to a mass spectrometer through electrospray ionization. An additional fractionation or enrichment step might be included for the detection of low-abundance proteins.
Multiple modes of mass spectrometry (MS) are used depending on the available instrumentation and the design of the experiment. For example, an Orbitrap instrument uses image current detection to measure ions that oscillate around the central electrode. Fourier transformation converts the signal from the time domain to the frequency domain, thus producing the spectrum. The Orbitrap is capable of a high level of resolution and mass accuracy , albeit with the trade-off of relatively longer acquisition times. A linear ion trap uses static and radiofrequency fields to confine ions within the trap. The radiofrequency voltage is adjusted to confine or eliminate desired ions for detection. The ion trap has fast acquisition times, but the spectra have lower levels of resolution and mass accuracy relative to those obtained using other instruments. Finally , a time-of-flight instrument measures the drift time of ions as they pass through a field-free region. Drift time is proportional to the mass-to-charge (m/z) ratio. Time-of-flight acquisition is fast, and the level of resolution varies depending on the instrument used.
Regardless of instrument type, the most common structure of an untargeted proteomics data set is data-dependent, that is, it consists of a survey MS scan followed by tandem mass spectrometry (MS/MS) of individual ions (peptides). The MS/MS spectra are then computationally searched against a database of known sequences to detect the peptide sequence. To produce a database containing theoretical tandem mass spectra, the sequences of known proteins are digested and fragmented in silico. 'Decoy' theoretical spectra are inserted by reversing the known sequences or applying randomly generated sequences. The best possible match of the experimental to theoretical spectrum is returned, and statistics are applied to return all detected peptide sequences on the basis of the desired false discovery rate.
into clinical practice 53 . One possibility is that mRNA-based biomarkers lack a direct link with protein activity and gene function, thus limiting their clinical applicability. An analysis of data on somatic copy number alterations, DNA methylation, mRNA and microRNA expression and that obtained from reverse-phase protein array (RPPA) protein expression data from four cancer types profiled by The Cancer Genome Atlas (TCGA) 54 demonstrated that, among all prognosis models that use such data, only the protein expression model for lung squamous cell carcinoma had a level of prognostic performance similar to that of a model based on clinical variables alone. Despite limited success, this study highlights the promise of protein measurements in clinical applications. In a study involving 44 colorectal cancer (CRC) cell lines 31 , MS-based global proteomics data better identified known drug-target associations and known drug-pathway associations than data on mutations, DNA copy number and mRNA expression. In a formal evaluation using random forest and fivefold crossvalidation, proteomics data enabled more sensitive predictions of responsiveness to four major drugs used in the treatment of CRC (5-fluorouracil, oxaliplatin, SN-38 and regorafenib) and the EGFR inhibitor erlotinib in 11 of 15 pair-wise comparisons with the performance of other omics modalities. Similarly, an analysis using MS-based global proteome profiling data from the CPTAC 25, 55 showed that proteomic profiles are strongly correlated with overall survival of patients with ovarian serous carcinomas; the prognostic performance of these signatures is currently under further evaluation. The findings of these studies demonstrate the potential of global proteome profiling in the discovery of prognostic and predictive cancer biomarkers. However, careful evaluations of the clinical utility of global proteome profiling will require more data sets with matched clinical and proteomic data and a sufficiently large sample size.
Protein modifications.
Protein modifications provide critical information on protein activity that is difficult to predict using genomic or even global proteomic data. Sustained proliferative signalling is arguably the most important hallmark of cancer 56 , and protein phosphorylation has a central role in proliferation-associated signal transduction. Many computational methods have been developed to infer the activity of signalling pathways by mapping cancer genomic data to precurated signalling networks and pathways 57 .
The accuracy of such inferences, although useful, is not easy to evaluate. The RPPA platform provides an antibody-based assay that enables the quantification of protein abundance and post-translational modifications of preselected proteins, and the value of this functional assay has been demonstrated in TCGA studies 58 . MS-based phosphoproteomic platforms provide deep coverage of the phosphoproteome. The CPTAC breast 24 and ovarian 25 cancer investigators identified a total of 62,679 and 24,464 phosphosites, with an average of 26,310 and 21,298 phosphosites per tumour, respectively. Most of the phosphosites were not already reported in existing databases such as PhosphoSitePlus 59 , thus improving our understanding of protein signalling. An obvious limitation of these studies is that the number of clinical specimens evaluated was too small to support robust clinical correlations.
In a proteogenomic analysis of PDX models of breast cancer, investigators validated some genomically predicted receptor tyrosine kinase targets; however, certain phosphorylation events such as overexpression of ARAF, BRAF and HSP90AB1 phosphosites cannot be explained by genomic data, suggesting that druggable phosphorylation events require direct proteomic detection 32 . In addition to analyses based on individual phosphosites or phosphoproteins, integrating global phosphorylation data with known kinase-target relationships or signalling pathways and networks enables the inference of the activity of specific kinase or kinase signalling pathways 60 . More importantly, existing knowledge of phosphosites and kinase-target relationships is far from complete, and signalling pathways and networks in public databases are not context-specific. Assays that enable a deeper analysis of the phosphoproteomes of a large number of samples might eventually enable the reconstruction of cancer typespecific, subtype-specific or tumour-specific signalling pathways and networks, which is critical for the further development of precision medicine.
Finally, integration of proteogenomics into clinical medicine provides a means to prioritize candidate cancer drivers. For example, a subset of one or more protein-coding genes in the same copy number amplification region might be implicated as cancer drivers on the basis of concordant overexpression of mRNAs, proteins and/or phosphoproteins 23, 24 .
Verifying proteomic markers The studies described above clearly demonstrate the power of integrative proteogenomics in generating candidate tumour biomarkers and drug targets. However, this approach suffers from the 'large P, small N' problem, in which the number of mutations, genes, proteins and modification sites analysed in a study far exceeds the number of samples that can be analysed within a reasonable time frame using global 'discovery' platforms (such as shotgun LC−MS/MS). Therefore, putative candidate biomarkers or drug targets identified in these studies must be further investigated in much larger sample sets before eventual clinical implementation. These qualification and verification studies [61] [62] [63] require precise and highly specific protein quantification, preferably using assays that can be readily harmonized across independent laboratories and run at moderate-to-high throughput in multiplex (such that many candidate biomarkers can be investigated while consuming a minimum amount of clinical material).
Next-generation sequencing (NGS) provides a powerful tool for both unbiased mutation discovery and targeted clinical assays designed to detect preselected mutations. By contrast, owing to technological limitations, the translation of protein-based biomarkers has lagged behind, resulting in a surprising dearth of novel protein biomarkers for use in clinical practice despite tremendous investments in biomarker discovery over the past few decades 64 . Immunohistochemistry currently remains the primary platform for clinical translation of protein biomarkers. Despite the widespread deployment of immunohistochemical assays as diagnostics and various technological advances enabling high-throughput, automated analysis of samples 65 , immunohistochemical assays continue to have analytical validity issues (such as inconsistent or limited specificity and reproducibility, semi-quantification and difficulties in multiplexing) that have rendered them unreliable as companion diagnostic tests [66] [67] [68] [69] [70] [71] [72] [73] . The costs and complexities associated with developing immunohistochemical assays for testing large numbers of candidate biomarkers emanating from genome-scale proteogenomic studies are also prohibitive. Likewise, shotgun LC−MS/MS as used in biomarker discovery is not transferable to clinical laboratories owing to low levels of sensitivity and selectivity, low throughput and high levels of complexity compared with more traditional clinical assays 64 . Although RPPA has been deployed in clinical trials 74 , the utility of this platform for biomarker verification and validation is greatly limited by the lack of availability of highly specific antibodies validated for the RPPA platform 75 . To address this unmet need for a platform that bridges the gap between proteomic and proteogenomic biomarker discovery to clinical validation, targeted MS approaches have been developed to provide multiplexed, precise quantification with a large dynamic range and high level of sample throughput [61] [62] [63] .
Targeted MS-based assays Selected/multiple reaction monitoring. The use of targeted MS to quantify proteins enables a moderate-to-high level of throughput with a good level of sensitivity and high specificity [61] [62] [63] [76] [77] [78] . In contrast to the shotgun approach, targeted MS focuses the full analytical capacity of the instrument on a discrete number of analytes of interest identified from proteomic and/or genomic discovery data 61, 62, 79 . By being selective in the proteins to be measured, targeted MS addresses the limitations of conventional shotgun-based methods (that is, reliance on annotated sequence databases, a lack of reproducibility of identifications, poor consistency in quantification and limited sensitivity for low-abundance analytes). Multiple MS-based acquisition schemes are capable of overcoming these challenges 80 . The most common approach, termed SRM, also commonly referred to as multiple reaction monitoring (MRM), involves the isolation and fragmentation of the targeted molecule with detection of specific fragments, confirmed by the use of internal standards 81, 82 (Fig. 4) .
Sub-femtomolar levels of sensitivity are routinely achieved, and the specificity of SRM/MRM can be very high. Because the triple-quadrupole mass spectrometers employed in SRM/MRM are not considered In targeted proteomics, proteins are converted to peptides through enzymatic (typically trypsin) digestion. The peptides are separated using liquid chromatography and introduced to a mass spectrometer through electrospray ionization. For low-abundance proteins, a fractionation or enrichment step might be performed, such as immunoaffinity enrichment (for example, using an immuno-selected/multiple reaction monitoring (SRM/MRM) assay). Stable isotope-labelled peptides are added as internal standards, and SRM analysis uses a triple-quadrupole mass spectrometer (QQQ). The first and third quadrupoles (Q1 and Q3) are used as mass filters separated by a collision cell for fragmentation (Q2). Q1 is tuned to pass the mass-to-charge ratio of the target ion (that is, the precursor ion) while filtering out all other ions. The targeted precursor ion is fragmented by collision-induced dissociation in Q2, which produces fragment ions (that is, product ions). Q3 is used as a mass filter to pass a single analyte-specific product ion for detection. The combination of a specific precursor-product ion pair is termed a transition. The data output is a peak area ratio of signal from the endogenous analyte peptide relative to that of the internal standard. By monitoring transitions, the sensitivity of the approach is improved over that of untargeted methods by removing chemical noise and increasing the signal-to-noise ratio for the analyte. Specificity is also improved by incorporating multiple levels of isolation and choosing highly specific transitions.
Multiplexing is achieved by sequentially stepping through a list of transitions. The acquisition of multiple transitions is typically performed on a timescale that is tens to hundreds of times faster than the chromatographic peak widths of eluting peptides, thus enabling multiple points to be measured across a single peak. The measurement of up to several hundred peptides is readily multiplexed into a single analytical run. cps, counts per second; MRM, multiple reaction monitoring; MS, mass spectrometry.
high-resolution instruments, limitations on the absolute level of specificity are typically overcome by incorporating the measurement of multiple fragments of a single analyte. High-resolution and highmass-accuracy instrumentation is used in an approach known as parallel reaction monitoring (PRM) 83, 84 . PRM is able to measure low-abundance analytes in very complex matrices, as the combination of high resolution, mass accuracy and acquisition of all fragment ions can provide an improved level of sensitivity and selectivity 85 . PRM will probably continue to grow in use, but SRM/MRM is the approach most likely to have immediate relevance in clinical proteogenomics applications owing to the sensitivity, availability in clinical laboratories, relatively low cost of instrumentation compared with PRM and proven robustness of the instrumentation.
SRM/MRM has been used extensively for the quantification of small molecules, including measurements performed in clinical reference laboratories of levels of metabolites that accumulate as a result of inborn metabolic defects 86, 87 . The same general principles of quantification of small molecules are applicable to proteomic applications 88 . Proteotypic peptides (that is, peptide sequences that are unique to the protein of interest and 'ionize well' in the mass spectrometer) are selected to represent the protein of interest. Selection of proteotypic peptides is an important step in method development, and several manuscripts describing selection rules, recommendations and considerations have been published 81, 89, 90 . Quantification is generally performed relative to internal standards, such as synthetic peptides with identical sequences to those of the analyte peptides but also incorporating heavy, stable, isotope-labelled amino acids. Typically, stable isotope labels are incorporated at the carboxyl-terminal arginine and/or lysine residues of tryptic peptides (for example, N 2 for lysine), and the absolute quantity of the material is determined using orthogonal techniques (such as amino acid analysis) 90 . Thus, the internal standards should have chemically and physically identical behaviours to those of the endogenous analytes but are distinguished by their massto-charge ratio in the mass spectrometer. The use of synthetic tryptic peptides controls for much of the preanalytical and all of the analytical assay variation, although it does not control for performance of the enzymatic digestion step, and thus larger, extended peptides and recombinant proteins can also be used as internal standards that improve accuracy and provide common reference materials [91] [92] [93] . The availability and renewability of the internal standards used in targeted proteomics render the approach highly amenable to harmonization and transfer across different laboratories [94] [95] [96] [97] . This approach is scalable for the generation of large numbers of assays 97, 98 , with much less time and fewer costs required in comparison to traditional immunohistochemical assays. Additionally, owing to the high specificity of the MS detector, targeted assays can be highly multiplexed, thus enabling the measurement of up to several hundred peptides in a single analytical run 97, [99] [100] [101] [102] , resulting in reduced costs and minimizing the use of clinical samples.
Enrichment of targets.
To produce actionable information on biomarkers that would affect a tumour board discussion, targeted SRM/MRM assay panels must be sufficiently sensitive to enable the quantification of protein networks in realword clinical specimens, especially in coreneedle biopsy samples and in 5-10 µm thick sections cut from formalin-fixed, paraffinembedded tumour blocks. Many clinical biomarkers require enrichment upstream of SRM/MRM in order to attain a sufficient level of sensitivity for quantification from limited amounts of clinical material. A variety of analyte enrichment options can be used, and these can involve physicochemical or affinity-based approaches. Physicochemical approaches typically use chromatographybased fractionation or the enrichment of broad analyte groups (for example, immobilized metal affinity chromatography for phosphorylated peptides), whereas affinity-based approaches typically employ antibodies targeting a specific sequence or motif (such as phosphorylated tyrosines or ubiquitylation). Affinity-based approaches typically enable a greater level of sample enrichment, more streamlined sample preparation requirements and higher throughput capabilities than physicochemical approaches 103 . Obviously, affinity-based enrichment is limited to targets for which high-affinity antibodies are either available or can be generated.
Enrichment can be performed at the protein or peptide level (that is, before or after digestion). The choice of enrichment of either proteins or peptides is largely dependent on the affinity of the reagents available. Note that the de novo generation of antibodies with affinity for short, linear sequences (including those with specific post-translational modifications) has shown a relatively high success rate (≥50%) in terms of generating antibodies that enable robust peptide immunoaffinity enrichment 98 . Immunoaffinity enrichment of the target protein or peptide, coupled with SRM/ MRM-based detection, produces highly sensitive and specific 'immuno-MRM' assays 104, 105 . Unlike conventional antibody-based immunoassays (such as immunohistochemistry, enzyme-linked immunosorbent assay (ELISA) and western blotting), immuno-MRM couples antibodybased enrichment of targets with a detection system (MS) that provides highly specific information on the amino acid sequence of the peptide. Protein lysates obtained from biospecimens (for example, biopsy samples) are proteolysed with trypsin, and reliably released tryptic peptide 'analytes' are enriched using antipeptide antibodies and can be detected using a mass spectrometer. Because the instrument is 'tuned' to detect only the analyte of interest (on the basis of its mass-to-charge ratio), the full analytical capacity is focused on analytes of interest, resulting in substantial improvements in sensitivity and selectivity compared with the untargeted shotgun modes of MS that are widely used in proteomic experiments. Furthermore, because the mass spectrometer provides a single amino acid level of resolution, and each analyte has a unique mass fingerprint, the inevitable nonspecific binding of proteins to reagent antibodies (interferences) can be excluded from further analysis. This feature of MRM also makes the development of antipeptide antibodies for immuno-MRM assays relatively straightforward compared with conventional immunoassays 98, 106 .
Applications. Use of MRM has enabled a broad range of applications, although such approaches have especially gained traction in biomarker verification studies 63, [76] [77] [78] 107, 108 ; this implementation synergizes with the more traditional protein immunoassays, as the assays can be used to select only candidate biomarkers that meet the appropriate initial performance criteria, thus sparing the costs in terms of both time and resources associated with developing traditional immunoassays designed to detect scores of candidates that might not verify. The technique can be used with a wide range of biological samples, including serum or plasma 77, 78, 109, 110 , urine 111, 112 , secretions 113 , tissue aspirates 114 , frozen tissue 115 , archived specimens (that is, formalin-fixed and paraffin-embedded) [116] [117] [118] and immortalized and primary cells 119, 120 . 125, 126 .
Limitations of MS-based assays
The many benefits of targeted MS-based assays described above (for example, precision, harmonization, multiplexing and specificity) need to be weighed against the limitations of this platform. First, although coupling immunoaffinity enrichment of peptides with targeted MS provides an enhanced level of sensitivity for the detection of proteins in clinical samples, the sensitivity of immuno-MS assays is currently not sufficient to support single-cell analyses, although progress is being made towards this goal 127, 128 . Unlike single-cell techniques (such as immunohistochemistry and flow cytometry), MS-based assays quantify the total amount of peptides and proteins across thousands of cells, similar to other extraction-based techniques such as ELISA and western blotting. Thus, applying targeted MS-based assays to certain clinical samples, such as plasma samples containing small numbers of circulating tumour cells, is not yet feasible, nor is it feasible to quantify differences in protein expression between individual cells. In addition, many proteins and post-translational modifications of clinical interest are detectable in clinical samples using immuno-MRM, although some are likely to remain below the lower limits of detection or quantification of the assay. In scenarios in which a sufficiently high-affinity antipeptide antibody cannot be developed, alternative approaches involving extensive sample fractionation can also provide highly sensitive, reproducible results [129] [130] [131] , albeit at lower throughput owing to the use of high-complexity fractionation protocols.
A second limitation is that subcellular localization or spatial resolution of protein expression (for example, in a specimen featuring different regions of a clonally heterogeneous tumour or at the invasive edge versus the hypoxic centre of a tumour) is not possible without additional sample processing such as macrodissection or microdissection. Third, developing an assay requires the availability of a reliable proteotypic peptide for measurement. For the majority of proteins, this factor is not an issue. However, in some scenarios, the availability of proteotypic peptides can be very limited. For example, in designing assays for specific post-translational modifications, the modification must reside on a peptide that is released reproducibly using a protease and is detectable by the mass spectrometer. Fourth, interlaboratory studies of MRM measurements have demonstrated that the protease (for example, trypsin) digestion step is the largest source of variation in MS analysis workflows 94 . Variations in digestion can occur on a sample-level basis and are analyte-dependent; therefore, intrasample quality controls, such as use of a cleavable internal standard that is digested in situ with the native protein, are the most effective method of monitoring digestion [132] [133] [134] . Finally, immuno-MRM assays require the generation of antibodies that enable enrichment of the target analyte, which can be both costly and time consuming; however, the high specificity of the mass spectrometer makes antibody development easier 98 than traditional immunoassay platforms, and many commercially available antibodies are likely to work in the immuno-MRM platform 135 .
Resources and recommendations
Software and database resources are available to support the development, data analysis and dissemination of the findings of targeted MRM assays. When designing assays, peptide selection is aided by searching online proteomics databases, such as those provided by the ProteomeXchange consortium 136 and the Global Proteome Machine 137 . Tools such as PeptidePicker 138 and MRMAssayDB 139 can be used to compile results and aid in the selection of the most appropriate surrogate peptides. Efforts to profile the SRM/ MRM parameters of peptides covering the entire human proteome have been made public in the past 4 years 140, 141 , with results available in SRMAtlas 142 . These and other data sets provide utility in supporting the selection of proteotypic peptides and coordinates for transition selection and optimization. Skyline 143 , a vendor-neutral tool designed specifically for targeted proteomics (although it is also applied to the analysis of small molecules), contains a variety of features and plug-in modules that enable researchers to identify peptides for assay development, optimize instrumental parameters and analyse targeted data.
Finally, several online repositories designed for targeted proteomics data are currently available. Panorama 144 is a database designed for experimental results that functions closely with Skyline.
PASSEL
145 is a repository for published experiments employing targeted data in which the contents can be mined for existing assay coordinates. Looking beyond databases of SRM/MRM transitions, the broader quantitative utility of assays is assembled in two online resources, the Quantitative Assay Database (QuAD) 146 and the CPTAC Assay Portal 147 . QuAD contains data on the characterization of standard peptides, including response curves, in addition to assay coordinates and optimization parameters. The CPTAC Assay Portal contains information on the best characterized targeted assays to date, with fit-for-purpose validated figures of merit, links to the characterization data and downloadable standard operating procedures designed to aid assay transferability and between-laboratory reproducibility. Multiple tiers of validation, using fit-for-purpose validation criteria, have been published 148 . Generally, traditional analytical figures of merit (for example, linearity, limits of detection, reproducibility, selectivity and stability) are also applicable to the validation of targeted proteomic assays based on SRM/MRM. A consensus document has been published summarizing recommendations for the generation, quantification, storage and handling of peptides used for MS-based assays 90 .
Clinical implementation
The development and clinical implementation of a targeted MRM-based assay in a clinical laboratory is a multistep process. Despite a decade of extensive literature on preclinical applications, targeted MS-based proteomic assays are only now beginning to be deployed in clinical laboratories or in clinical trials, as a critical mass of well characterized, targeted MSbased assays are becoming available for the quantification of panels of cancer-associated proteins 147 . The NCI is supporting efforts to drive these protein assays into clinical trials through CPTAC's Proteogenomic Translational Research Centers as well as the Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) Network 149 . One of the earliest translations of a targeted MS-based proteomic assay to the clinical environment was the measurement of serum thyroglobulin levels, an important cancer biomarker used in monitoring patients receiving treatment for differentiated thyroid carcinoma 150 . The high prevalence of autoantibodies capable of interfering with FDA-approved serum thyroglobulin immunoassays in samples from patients with thyroid cancer provided the motivation for the development of a targeted MS-based assay 151 . Autoantibodies to thyroglobulin interfere with the formation of sandwiches in immunometric assays and can cause false-negative results in ~25% of patients. For the same reasons, false-positive results are also possible for the same patients when competitive radioimmunoassays are used. Naturally occurring anti-reagent antibodies also interfere with immunoassays and can cause incorrect results. These errors have clinical consequences for patients, as false-positive results can lead to unnecessary clinical interventions, and false-negative results inevitably lead to a delay in diagnosis and therapy. Fortuitously, the digestion of serum with trypsin in preparation for MRM analysis degrades interfering autoantibodies, and the enrichment of thyroglobulinderived peptides using peptide-specific antibodies enables the detection of very low concentrations of such peptides, which serve as a validated surrogate for the protein 152, 153 . The greatest hurdle in the quantification of thyroglobulin levels using MRM was the very low concentration of thyroglobulin in human serum. Indeed, for each peptide liberated from thyroglobulin, >40,000,000 peptides are liberated from albumin in the same complex mixture (based on the average mass concentration of albumin versus that of thyroglobulin in human serum of 4 g/dl versus 1 ng/ml) 154 . Although LC−MS/MS enables the resolution of an impressive number of peptides, resolution was not sufficient in this scenario. The introduction of an enrichment step involving an antipeptide antibody targeting a proteotypic peptide derived from thyroglobulin provided an approximately 10,000-fold enrichment, resulting in a lower limit of quantification of ~3 ng/ml (reF.
150
).
Affinity reagents and sample preparation conditions have been optimized, and the assay was successfully replicated in other clinical laboratories [155] [156] [157] [158] . The assay is now sufficiently sensitive (with a lower limit of detection of 0.15 ng/ml) and efficient such that it has replaced traditional immunoassays used for the quantification of thyroglobulin levels in patient samples and is now offered by six clinical reference laboratories in North America. This step marks an important advance for the field of clinical MS.
An improved level of concordance of results between different laboratories, relative to those obtained using immunoassays, was one of the major hopes of targeted proteomics 153 . In order to evaluate the level of agreement between independent measurements of thyroglobulin levels, a group of clinical laboratories collaborated on a small project in which leftover patient samples with and those without autoantibodies were analysed using four different immunoassays at the same centre and LC−MS/MS assays at four different centres 159 . The results demonstrated that, even though the methods used for digestion and calibration were different in each laboratory, the LC−MS/MS assays had a higher level of inter-assay agreement (mean r 2 = 0.98; standard deviation 11.6%) than four different automated immunoassays (r 2 = 0.96; standard deviation 21.9%) despite the latter being run in the same laboratory. Additional collaboration demonstrated that the clinical performance of two LC−MS/MSbased assays in predicting patient outcomes was essentially equivalent and that LC−MS/ MS-based assays are at least as effective as immunoassays in determining serum thyroglobulin levels and thus influencing care of patients 160 .
The road from hypothesis to disseminated technology, in the form of clinical measurement procedures, was predictably long. More than 10 years elapsed between the first proof-of-principle experiments to the most recent version of the serum thyroglobulin assay. During that time, the assay was iteratively improved and tested using the pre-validation experiments now outlined in the Clinical and Laboratory Standards Institute (CLSI) document C62-A 161, 162 and elsewhere 147, 161, 163 . The lessons learned from the success of the serum thyroglobulin assay will undoubtedly shorten the time required to implement future MS-based measurement procedures into the clinical laboratory.
Beyond thyroglobulin, additional targeted MS-based assays are making their way towards clinical use 164, 165 . For example, in patients with breast cancer whose tumours were found to be HER2-positive using immunohistochemistry and fluorescence in situ hybridization (FISH), analysis of tumour tissue samples using a targeted MRM assay revealed a wide dynamic range of HER2 expression, ranging across multiple orders of magnitude 165 . HER2 levels, as measured using MRM, are predictive of overall survival in the supposedly homogeneous subgroup of patients with HER2-positive breast cancer (identified by standard immunohistochemistry and FISH) 165 .
In another example, MRM was used to quantify two plasma proteins whose levels accurately distinguished benign from malignant nodules in the Pulmonary Nodule Plasma Proteomic Classifier (PANOPTIC) trial in patients with a pretest probability of cancer ≤50% 110 . In other areas of medicine, MRM is being investigated in a trial to quantify changes in a panel of protein biomarkers of cardiovascular disease before and after initiation of statin therapy (NCT02402803), while PRM is being used to molecularly characterize bacteria in tracheal and urine samples collected from patients with infection (NCT03475472).
The high multiplex capacity of MRMbased measurements will further enable the cost-effective development and deployment of panels of proteomic assays designed to complement NGS panels that are currently widely used in clinical trials. This is important because findings obtained using different FDA-approved immunoassays are often not in agreement with one another 151 . Even though the assays are initially cleared as 'substantially equivalent' , calibration often drifts over time until assays are no longer harmonized. Directly detecting peptides using targeted MS (rather than the indirect assay signals observed using traditional immunoassays) might enable laboratories to be more successful in calibrating different laboratory-developed tests to achieve higher levels of agreement. In a head to head comparison of serum prostate-specific antigen measurements made using either an ELISA (approved by the Clinical Laboratory Improvement Amendments (CLIA) of 1988) voLume 16 | APRIL 2019 | 263 NATuRe RevIewS | ClINICal ONCOlOgy P e r s P e c t i v e s Box 1 | Criteria to demonstrate medical necessity for oncological biomarker panels 179 • Biomarkers must have proven clinical validity and/or utility.
• Supporting the medical necessity of the service requires acceptance and/or uptake of specific testing into patient management. Physicians must be sufficiently familiar with all specific biomarkers that they order such that all tests might provide clinically actionable information.
• Providers managing patients with cancer or related conditions must demonstrate that the biomarkers will be used to assist in the management and/or treatment of the beneficiary.
• Robust peer-reviewed evidence is required to support the use of combination panels designed to detect and/or quantify multiple biomarkers, particularly regarding their alleged composite clinical validity and/or utility. For example, multiple, diverse biomarkers (such as diagnostic, monitoring, prognostic or predictive biomarkers) can achieve medical necessity only when it is clearly evident how each biomarker can individually contribute to analytical performance.
or a targeted MS-based assay (high-pressure, high-resolution separation with intelligent selection and multiplexing (PRISM-SRM)), the MS-based assay had greater levels of sensitivity than and equivalent levels of reproducibility to the ELISA 166 .
Regulatory considerations
In the USA, the translation of novel assays into patient care is overseen by the Centers for Medicare and Medicaid Services (CMS) and the FDA 167 . Whereas the CMS oversees the accreditation of laboratories under the CLIA of 1988, the FDA evaluates the safety and effectiveness of in vitro diagnostic medical devices (IVDs) for use in patient care. The FDA now recognizes a standards guideline, C62-A 161 , from the CLSI that describes analytical validation studies for LC-MS assays and is primarily focused on the detection of small molecules (for example, metabolites 168, 169 and therapeutic drugs 168 ). This important guideline provides a set of standards that could be referenced during the approval and clearance of assays in the future.
Currently, all targeted proteomic MS-based assays used in clinical laboratories are laboratory-developed tests (a subset of IVDs) that are designed, manufactured and used in a single laboratory 170, 171 . No laboratory-developed tests using targeted proteomics and LC-MS have yet been approved for clinical use by the FDA or, to our knowledge, by any similar regulatory body serving another country or geographical area. Although no FDA guidance documents that describe the analytical study requirements for targeted LC-MS-based proteomic IVDs currently exist, the requirements will follow the standard template for approval of other proteomics-based IVDs 64 , with some additional technology-specific studies and information that will need to be provided. The FDA and the NCI's CPTAC held a public workshop on analytical validation of protein and peptide LC-MS-based assays 172, 173 . The FDA has also held two public workshops on the use of proteomics technologies in the clinic and the analytical validation of protein and peptide LC-MSbased assays. The transcripts, presentations and a discussion paper from these workshops are publicly available 174, 175 .
Reimbursement
Potential mechanisms of reimbursement for clinical proteomic testing differ country by country. Because the USA is a major market for such tests, and also owing to the likelihood that the USA will be the first country to have such tests approved, reimbursement mechanisms in the USA are covered here. The pathway to getting a novel proteomic assay covered by a payer, either public or private, requires considerable investment of the time and/or other resources of the performing laboratory to satisfy the various stakeholders, including insurance companies, benefits management companies and federal regulatory bodies such as the FDA and the American Medical Association (the body that issues the Current Procedural Terminology codes required for payment). To convince all of these stakeholders that a new test is safe, effective and medically necessary, and, moreover, worthy of reimbursement in a climate of ever increasing cost consciousness, is a daunting task.
The CMS set payment levels in the USA according to the Protecting Access to Medicare Act (PAMA) and, historically, private insurers in the USA have set their own reimbursements in relation to CMS levels. The provisions of the PAMA relevant to laboratory reimbursement include defining an Advanced Diagnostic Laboratory Test (ADLT) as "…an analysis of multiple biomarkers of DNA, RNA or proteins combined in a unique algorithm to yield a single patient specific result" (42 CFR § 414.502). An ADLT must also be performed for clinical purposes in one laboratory and, as such, the reimbursement decision is made for both a specific test and a specific laboratory. Pricing is initially based upon the list price of the performing laboratory, followed by a shift to the weighted median of private payer rates. For newer tests that report actual analyte concentrations, and not the results of an algorithm, the CMS sets prices either by 'cross-walking' (establishing that the new test is similar to an old test with a set payment price and using that price with or without a multiplier) or 'gap-filling' (a more holistic analysis by the CMS that might take into account the resources required to perform the test when calculating the price). The effort expended by laboratories to lobby for favourable payment decisions from the CMS, private payers and laboratory benefits management companies is often considerable.
Title XVIII of the Social Security Act states that no Medicare payment shall be made for items or services that "are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of malformed body member" (Social Security Act §1862(a)(1)(A)) 176 .
Services not considered medically necessary are often referred to as experimental and/or investigational. Several criteria exist to guide the eligibility of biomarker panels designed for use in patients with cancer for local coverage (Box 1). Unsurprisingly, novel tests are usually not considered medically necessary when first offered. Publication of data from a single study showing the analytical accuracy of the test or the associated clinical benefits is usually not sufficient for a test to be considered medically necessary, although, confusingly, some tests have been covered for reimbursement for years • other independent, objective evaluations or systematic literature reviews that substantively contribute to the evidence base, including but not restricted to emerging NIH (National Cancer Institute) guidelines for the accrual of evidence of clinical validity and/or utility of genomicsbased and/or proteomics-based assays; no prescriptive format for such systematic reviews currently exists, although the documentation (submitted to Novitas) for reconsideration purposes should include the following three elements: -Some type of recurring and/or periodic committee structure, comprising, as a minimum, qualified biomathematicians and/or methodologists, molecular pathology laboratory specialists and relevant clinicians (such as oncologists) -evidence of active sharing of the findings of critical evaluations in a manner that enables sufficiently broad input into the process and a feasibly wide level of acceptance of this process by representative molecular pathology stakeholders; there is no preference between such a committee being based at a single site or even rotating among several sites -Transparency of the biomarker evaluations to be recorded via minutes (or a summary of minutes) despite the availability of ample evidence of clinical obsolescence (including outdated tumour biomarkers, such as prostatic acid phosphatase) 177 . Several sources provide information supporting the ideal criteria for local coverage determination (Box 2).
The VeriStrat test offered by Biodesix is a proteomic test that has successfully navigated a variety of systemic obstacles in order to obtain reimbursement from many insurers. This test is a matrix-assisted laser desorption/ionization (MALDI) MS-based assay for the analysis of serum samples that uses a proprietary algorithm to generate a score that directs the appropriate administration of therapy in patients with NSCLC. Evidence cited in several of the insurers' medical policies 178 includes data from both prospective, randomized controlled trials and from retrospective studies published in peer-reviewed journals and a cost-utility analysis. Policies generally limit the use of the test to a very narrow clinical indication.
Conclusions
Precision oncology approaches based on tumour genomics alone have benefited a subset of patients with cancer, although many patients do not respond to therapies selected following sequencing of their tumour genome (and most initial responders will ultimately develop resistance). Therefore, a deeper, more comprehensive readout of tumour biology is required in order to predict tumour phenotype with respect to drug response. Towards this end, proteomic data are being used to annotate tumour genomes (with respect to which genomic features are expressed) and to provide information on tumour biology that cannot be discerned using genomic profiles alone (for example, posttranslational modifications and epigenetic causes of inactivation, both of which might not involve detectable genetic alterations). The integration of personalized genome information, coupled with data regarding its execution at the protein level, is expected to soon become an accepted component in the practice of precision oncology.
Targeted MS-based assays have matured technically over the past decade and are now capable of achieving a level of analytical performance comparable to that of FDA-approved immunoassays and other affinity-reagent-based assays. These assays provide a bridge between the discovery of candidate biomarkers and biomarker verification and are now beginning to enter clinical use. The value of targeted MS-based assays, and the additional information provided regarding protein expression and post-translational modifications, needs to be established through the results of clinical trials, and this is an area of intense activity.
